Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain Amylo®
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a CT-based method for regional amyloid-beta quantification in Alzheimer's disease, establishing cutoffs to classify patient subgroups across cognitive stages.
Area Of Science
- Neurology
- Radiology
- Biomarkers
Background
- Amyloid-beta (Aβ) plaques are central to Alzheimer's disease (AD) pathology.
- Positron emission tomography (PET) enables Aβ quantification, but often requires MRI.
- Regional Centiloid scales (rdcCL) were developed for regional Aβ deposition analysis.
Purpose Of The Study
- Establish robust regional Aβ cutoffs using a commercialized CT-based platform (BeauBrain Amylo).
- Explore the prevalence of Aβ subgroups defined by global, regional, and striatal cutoffs across cognitive stages.
Main Methods
- Utilized data from 2,428 individuals from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research project.
- Calculated regional Aβ cutoffs via Gaussian Mixture Modeling.
- Classified participants into subgroups based on Aβ positivity across cognitive stages (cognitively unimpaired, mild cognitive impairment, dementia).
Main Results
- CT-based and MRI-based global Aβ cutoffs showed high comparability.
- Regional cutoffs revealed modality-specific differences due to segmentation.
- Specific Aβ subgroup prevalences varied across cognitive stages and brain regions.
Conclusions
- Established robust regional Aβ cutoffs using a CT-based rdcCL method.
- Demonstrated clinical utility in classifying amyloid subgroups across cognitive stages.
- Highlighted the importance of regional Aβ quantification for AD diagnosis and treatment.

